This is a great point about target markets/numbers - I am going to try and do some research and check my assumptions with the company over coming days.
We know that initial target markets are Aus/UK/Sing, so lets focus on them, and then consider the next likely markets to enter.
A $50m market cap is priced for failure with no working product. 50c is ~ $250m market cap, not at all unreasonable as a starting point, when it becomes clear that the product is reliable, in demand, and clinically backed.
After Bruce Thompson studies, I think us shareholders can have confidence that the product works and is of clinical relevance. So it makes sense to start to compile some target markets and have a guess at the penetration rates that could be achieved - which will directly flow through to the companies valuation.
RSH Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
